Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 46, 2010, Pages 20003-20008

  Namdar, Mandana ^a   Perez, Gisela ^a   Ngo, Lang ^a   Marks, Paul A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Apoptosis; Chk2; DDIT3 CHOP GADD153; Histones; H2AX

Indexed keywords

ANTINEOPLASTIC AGENT; CHECKPOINT KINASE 2; DNA; DOUBLE STRANDED DNA; DOXORUBICIN; ETOPOSIDE; GAMMA HISTONE H2AX; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; HISTONE H2AX; SHORT HAIRPIN RNA; TUBACIN; UNCLASSIFIED DRUG; VORINOSTAT;

APOPTOSIS; CELL STRAIN LNCAP; CELL STRESS; CELL TRANSFORMATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SENSITIZATION; UPREGULATION;

EID: 78650575875     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1013754107     Document Type: Article

References (43)

1. Dokmanovic M, Clarke C, Marks PA (2007) Histone deacetylase inhibitors: Overview and perspectives. Mol Cancer Res 5:981-989.
2. Richon VM, Garcia-Vargas J, Hardwick JS (2009) Development of vorinostat: Current applications and future perspectives for cancer therapy. Cancer Lett 280:201-210.
3. Mehnert JM, Kelly WK (2007) Histone deacetylase inhibitors: Biology and mechanism of action. Cancer J 13:23-29.
4. Ropero S, Esteller M (2007) The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1:19-25.
5. Namdar M, Marks PA (2010) in Histone Deacetylase Inhibitors in Medicine, eds El- Osta A, Karagiannis TC (Research Signpost), pp 9-39.
6. Duvic M, et al. (2009) Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 9:412-416.
7. Marks PA, Breslow R (2007) Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25:84-90.
8. Campas-Moya C (2009) Romidepsin for the treatmentof cutaneous T-cell lymphoma. Drugs Today (Barc) 45:787-795.
9. Ma X, Ezzeldin HH, Diasio RB (2009) Histone deacetylase inhibitors: Current status and overview of recent clinical trials. Drugs 69:1911-1934.
10. Bradner JE, et al. (2010) Chemical phylogenetics of histone deacetylases. Nat Chem Biol 6:238-243.
11. Parmigiani RB, et al. (2008) HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redoxregulation. Proc Natl AcadSci USA 105:9633-9638.
12. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL (2003) Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 100:4389-4394.
13. Bali P, et al. (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280:26729-26734.
14. Hubbert C, et al. (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417: 455-458.
15. Kawaguchi Y, et al. (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115:727-738.
16. Rao R, et al. (2008) HDAC6 inhibition enhances 17-AAG - mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 112:1886-1893.
17. Marcus AI, et al. (2005) The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res 65:3883-3893.
18. Hideshima T, et al. (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 102:8567-8572.
19. Bazzaro M, et al. (2008) Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res 14:7340-7347.
20. Kawada J, Zou P, Mazitschek R, Bradner JE, Cohen JI (2009) Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis. J Biol Chem 284:17102-17109.
21. Rodriguez-Gonzalez A, et al. (2008) Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Res 68:2557-2560.
22. Lin L, Qian Y, Shi X, Chen Y (2005) Induction of a cell stress response gene RTP801 by DNA damaging agent methyl methanesulfonate through CCAAT/enhancer binding protein. Biochemistry 44:3909-3914.
23. Whitney ML, Jefferson LS, Kimball SR (2009) ATF4 is necessary and sufficient for ER stress-induced upregulation of REDD1 expression. Biochem Biophys Res Commun 379: 451-455.
24. Zinszner H, et al. (1998) CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev 12:982-995.
25. Xu W, Ngo L, Perez G, Dokmanovic M, Marks PA (2006) Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA 103:15540-15545.
26. Mullen P (2004) PARP cleavage as a means of assessing apoptosis. Methods Mol Med 88:171-181.
27. Falck J, Mailand N, Syljuåsen RG, Bartek J, Lukas J (2001) The ATM-Chk2-Cdc25A checkpoint pathway guards againstradioresistant DNA synthesis. Nature 410:842-847.
28. Abraham RT (2001)Cell cyclecheckpoint signaling through the ATM and ATR kinases. Genes Dev 15:2177-2196.
29. Rahman A, Carmichael D, Harris M, Roh JK (1986) Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Res 46: 2295-2299.
30. Hande KR, et al. (1984) Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res 44:379-382.
31. Kelly WK, et al. (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23: 3923-3931.
32. Karagiannis TC, El-Osta A (2006) Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene 25:3885-3893.
33. Kim MS, et al. (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63:7291-7300.
34. Marchion DC, et al. (2004) Sequence-specific potentiation of topoisomerase II inhibitors bythe histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 92:223-237.
35. Martinez-López W, Folle GA, Obe G, Jeppesen P (2001) Chromosome regions enriched in hyperacetylated histone H4 are preferred sites for endonuclease- and radiationinduced breakpoints. Chromosome Res 9:69-75.
36. Zhang Y, et al. (2007) Attenuated DNA damage repair by trichostatin A through BRCA1 suppression. Radiat Res 168:115-124.
37. Adimoolam S,et al. (2007) HDA Cinhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci USA 104:19482-19487.
38. Munshi A, et al. (2005) Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11:4912-4922.
39. Kovacs JJ, et al. (2005) HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18:601-607.
40. Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and coregulates major cellular functions. Science 325:834-840.
41. Chen CS, et al. (2007) Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 67:5318-5327.
42. Sun Y, Xu Y, Roy K, Price BD (2007) DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity. Mol Cell Biol 27:8502-8509.
43. Boyault C, et al. (2006) HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBO J 25:3357-3366.